Safety and efficacy of micropulse in pediatric eyes with refractory glaucoma.

IF 2.1 4区 医学 Q2 OPHTHALMOLOGY
Indian Journal of Ophthalmology Pub Date : 2025-03-01 Epub Date: 2025-02-21 DOI:10.4103/IJO.IJO_1066_24
Raajaraajeshwari Sivasubramanian, Kumar Siddharth, Vijayalakshmi A Senthilkumar, Iswarya Mani, Sharmila Rajendrababu
{"title":"Safety and efficacy of micropulse in pediatric eyes with refractory glaucoma.","authors":"Raajaraajeshwari Sivasubramanian, Kumar Siddharth, Vijayalakshmi A Senthilkumar, Iswarya Mani, Sharmila Rajendrababu","doi":"10.4103/IJO.IJO_1066_24","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To analyze the safety and efficacy of micropulse transscleral cyclophotocoagulation (MP-TSCPC) in pediatric eyes with refractory glaucoma.</p><p><strong>Design: </strong>Hospital-based prospective interventional study.</p><p><strong>Methods: </strong>Patients less than 18 years of age, receiving MP-TSCPC between December 1, 2022 and May 31, 2023 with at least three follow-ups within 6 months period, were included in the study. Post-laser evaluation was done at day 1, 1 month, 3 months, and 6 months. Success outcomes were calculated at 1, 3, and 6 months follow-up.</p><p><strong>Results: </strong>A total of 23 eyes of 23 patients were included in the study. Mean intraocular pressure (IOP) lowering agents (P = 0.041) had significant change compared to the baseline value; however, the change was insignificant when eyes requiring additional IOP-lowering surgeries during the follow-up period were excluded. There was a significant reduction in IOP at each follow-up visit compared to the baseline (P = 0.000014). Two (8.6%) eyes required additional intervention within 1-month follow-up, another six eyes (26%) between 1-3 months, and three eyes (13%) between 3-6 months of MP-TSCPC. Total success was highest at 56.5% (13 eyes) at 1-month follow-up and at least 34.7% (8 eyes) at 6-month follow-up. No major complications were reported in our study.</p><p><strong>Conclusion: </strong>MP-TSCPC was found to be safe and effective in pediatric population. However, we observed a gradual reduction in the success with time, and thus, it can be individualized to patients with high risk for incisional surgery or those requiring immediate IOP reduction.</p>","PeriodicalId":13329,"journal":{"name":"Indian Journal of Ophthalmology","volume":"73 Suppl 2","pages":"S227-S231"},"PeriodicalIF":2.1000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/IJO.IJO_1066_24","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/21 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To analyze the safety and efficacy of micropulse transscleral cyclophotocoagulation (MP-TSCPC) in pediatric eyes with refractory glaucoma.

Design: Hospital-based prospective interventional study.

Methods: Patients less than 18 years of age, receiving MP-TSCPC between December 1, 2022 and May 31, 2023 with at least three follow-ups within 6 months period, were included in the study. Post-laser evaluation was done at day 1, 1 month, 3 months, and 6 months. Success outcomes were calculated at 1, 3, and 6 months follow-up.

Results: A total of 23 eyes of 23 patients were included in the study. Mean intraocular pressure (IOP) lowering agents (P = 0.041) had significant change compared to the baseline value; however, the change was insignificant when eyes requiring additional IOP-lowering surgeries during the follow-up period were excluded. There was a significant reduction in IOP at each follow-up visit compared to the baseline (P = 0.000014). Two (8.6%) eyes required additional intervention within 1-month follow-up, another six eyes (26%) between 1-3 months, and three eyes (13%) between 3-6 months of MP-TSCPC. Total success was highest at 56.5% (13 eyes) at 1-month follow-up and at least 34.7% (8 eyes) at 6-month follow-up. No major complications were reported in our study.

Conclusion: MP-TSCPC was found to be safe and effective in pediatric population. However, we observed a gradual reduction in the success with time, and thus, it can be individualized to patients with high risk for incisional surgery or those requiring immediate IOP reduction.

求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.80
自引率
19.40%
发文量
1963
审稿时长
38 weeks
期刊介绍: Indian Journal of Ophthalmology covers clinical, experimental, basic science research and translational research studies related to medical, ethical and social issues in field of ophthalmology and vision science. Articles with clinical interest and implications will be given preference.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信